Target intelligence / Profile preview

Beta-lactamase TEM (TEM)

Target
TEM
Molecular classification
Enzyme, Hydrolase, Class A beta-lactamase, Serine beta-lactamase
01

Overview

Beta-lactamase TEM is a plasmid-mediated class A serine beta-lactamase enzyme primarily found in Gram-negative bacteria, such as Escherichia coli and Klebsiella pneumoniae. It plays a critical role in bacterial resistance by catalyzing the hydrolysis of the four-membered beta-lactam ring in penicillins and early-generation cephalosporins, rendering these antibiotics inactive. Over time, numerous mutations in the blaTEM gene have led to the emergence of extended-spectrum beta-lactamases (ESBLs) and inhibitor-resistant TEM (IRT) variants, which significantly expand the enzyme's substrate profile to include third-generation cephalosporins and monobactams.

To combat this resistance mechanism, beta-lactamase inhibitors such as clavulanic acid, tazobactam, and avibactam are co-administered with beta-lactam antibiotics. These inhibitors act either as suicide substrates that covalently and irreversibly bind to the active-site serine residue or as reversible transition-state analogs, thereby protecting the companion antibiotic from degradation and restoring its therapeutic efficacy. However, the rapid evolution of TEM variants remains a major therapeutic challenge, as mutations can alter the active site configuration to evade both traditional and novel inhibitors.

Other names
TEM-type beta-lactamaseTEM-1 beta-lactamaseTEM-1PenicillinaseIRT-4Beta-lactamase TEM-1blaTEM
02

Mechanism of action

Covalent or reversible inhibition of the active-site serine residue of the beta-lactamase enzyme, preventing the hydrolysis of co-administered beta-lactam antibiotics.

03

Biological functions

Antibiotic catabolic processHydrolysis of beta-lactam antibioticsBacterial defense mechanism
04

Disease associations

Infection
05

Safety considerations

Development of inhibitor-resistant TEM (IRT) variantsOverexpression of beta-lactamase overcoming inhibitionOff-target effects of companion antibiotics (e.g., hypersensitivity, renal toxicity, gastrointestinal distress)Selection of multi-drug resistant bacterial strains
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

blaTEM gene detectionBeta-lactamase activity assayBacterial resistance profilingMinimum inhibitory concentration (MIC) reduction

Beyond the preview

Go deeper on Beta-lactamase TEM (TEM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-lactamase TEM (TEM).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call